PDCD1 and lung carcinoma: Multiple mAb candidates that target the PD-1/PD-L1 immune checkpoint have demonstrated reliable responses in tumors, including lung cancer, whereas some mAb candidates have shown remarkable antitumor effects in different clinical trials.